Stockscreener 앱 받기
23.13
10.04%
2.11
시간 외 거래:
23.13
전일 마감가:
$21.02
열려 있는:
$21.5
하루 거래량:
477.10K
Relative Volume:
0.79
시가총액:
$833.10M
수익:
$13.00M
순이익/손실:
$-68.87M
주가수익비율:
-10.38
EPS:
-2.2276
순현금흐름:
$-76.68M
1주 성능:
-3.99%
1개월 성능:
-22.54%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$21.18
$24.15
1주일 범위
$20.64
$24.92
52주 변동 폭
$13.88
$33.20
Evommune Inc Stock (EVMN) Company Profile
명칭
Evommune Inc
전화
(650) 223-7745
주소
1841 PAGE MILL RD, PALO ALTO
Compare EVMN vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EVMN
Evommune Inc
|
23.13 | 757.11M | 13.00M | -68.87M | -76.68M | -2.2276 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Evommune Inc Stock (EVMN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 개시 | Oppenheimer | Outperform |
| 2026-01-08 | 개시 | Raymond James | Strong Buy |
| 2026-01-06 | 개시 | H.C. Wainwright | Buy |
| 2025-12-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-01 | 개시 | Evercore ISI | Outperform |
| 2025-12-01 | 개시 | Leerink Partners | Outperform |
| 2025-12-01 | 개시 | Morgan Stanley | Overweight |
| 2025-12-01 | 개시 | William Blair | Outperform |
모두보기
Evommune Inc 주식(EVMN)의 최신 뉴스
Evommune (NYSE:EVMN) Trading Up 10.2%Still a Buy? - MarketBeat
Evommune (NYSE:EVMN) Stock Price Down 7.6%Should You Sell? - MarketBeat
This Evommune analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
Evommune, Inc.(NYSE: EVMN) added to S&P Global BMI Index - marketscreener.com
EVMN Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Planet Labs (NYSE:PL) Revenue Beats, Lags NYSE Index on Profit - Kalkine Media
Evommune (NYSE:EVMN) Upgraded at Clear Str - MarketBeat
Evommune stock sees RS rating rise to 91 - MSN
Nvidia To Rally Around 79%? Here Are 10 Top Analyst Forecasts For Wednesday - Sahm
Technical Analysis of Evommune, Inc. (NYSE:EVMN) - TradingView
Evommune (EVMN) Insider Trading Activity 2026 - MarketBeat
Analysts Set Expectations for Evommune FY2027 Earnings - MarketBeat
Evommune: Buy Rating Backed by 2026 Catalyst Rich Pipeline and Differentiated MRGPRX2 Dermatology Franchise - TipRanks
H.C. Wainwright cuts Evommune stock price target on dilution - Investing.com UK
H.C. Wainwright cuts Evommune stock price target on dilution By Investing.com - Investing.com India
HC Wainwright Cuts Evommune (NYSE:EVMN) Price Target to $50.00 - MarketBeat
Evommune (EVMN) Stock Forecast and Price Target 2026 - MarketBeat
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
EVMN Stock: HC Wainwright & Co. Lowers Price Target to $50 | EVM - GuruFocus
Clear Street initiates Evommune stock with buy rating on drug potential - Investing.com India
Clear Street initiates Evommune stock with buy rating on drug potential By Investing.com - Investing.com South Africa
Evommune (NYSE:EVMN) Stock Price Up 7.5%Should You Buy? - MarketBeat
Evommune, Inc. Common Stock (NY: EVMN - The Chronicle-Journal
Evommune, Inc. Common Stock (NYSE:EVMN) Stock Quote - The Chronicle-Journal
Leerink reiterates Evommune stock rating after conference chat By Investing.com - Investing.com India
Leerink reiterates Evommune stock rating after conference chat - Investing.com Nigeria
RBC Capital initiates Evommune stock with outperform rating By Investing.com - Investing.com Canada
RBC Capital initiates Evommune stock with outperform rating - Investing.com
Evommune, Inc. (NYSE:EVMN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
1 Under‑the‑Radar Biotech to Buy for Potential 10X Growth in the Next Decade - AOL.com
Evommune initiated with an Outperform at RBC Capital - TipRanks
Evommune (NYSE:EVMN) Trading Down 6.7%Here's What Happened - MarketBeat
Evommune (EVMN) Earnings Loss Deepens Narrative Around Heavy Spending And Unprofitability - Sahm
Evommune (NYSE:EVMN) Trading 6.9% HigherTime to Buy? - MarketBeat
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlight - PharmiWeb.com
Evommune Reports Q4 2025 Results and Pipeline Progress - TipRanks
Evommune reports Q4 EPS ($1.43), consensus (84c) - TipRanks
Evommune, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights - The Joplin Globe
This Biotech Stock Nearly Doubled In Value Today Morning – What’s Driving Investor Optimism? - Stocktwits
Evommune, Inc. announced that it has received $125.300499 million in funding - marketscreener.com
Evommune, Inc.: Lead in MRGPRX2 Modulation and Differentiated EVO756 Profile Support Buy Rating - TipRanks
EVMN SEC FilingsEVOMMUNE INC 10-K, 10-Q, 8-K Forms - Stock Titan
EVMN Technical Analysis & Stock Price Forecast - Intellectia AI
Evommune Inc (EVMN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):